Table 1 Relationship between heregulin, ErbB1-4, pErbB1-4 and clinicopathological factors
From: Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
| Heregulin | EGFR | pEGFR | ErbB2 | pErbB2 | ErbB3 | pErbB3 | ErbB4 | pErbB4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | No. (percent) | P value | |
| Age | |||||||||||||||||||
| <66 | 78 | 38 (49) | NS | 46 (59) | NS | 27 (35) | NS | 14 (18) | 0.018 | 12 (15) | NS | 28 (36) | NS | 19 (24) | NS | 17 (22) | NS | 9 (12) | NS |
| ≥66 | 77 | 33 (43) | 33 (43) | 23 (30) | 27 (35) | 18 (23) | 36 (47) | 21 (27) | 16 (21) | 16 (21) | |||||||||
| Gender | |||||||||||||||||||
| Male | 90 | 41 (46) | NS | 45 (50) | NS | 26 (29) | NS | 27 (30) | NS | 20 (22) | NS | 41 (46) | NS | 22 (24) | NS | 17 (19) | NS | 16 (18) | NS |
| Female | 65 | 30 (46) | 34 (52) | 24 (37) | 14 (22) | 10 (15) | 23 (35) | 18 (28) | 16 (25) | 9 (4) | |||||||||
| Site | |||||||||||||||||||
| Colon | 106 | 45 (42) | NS | 52 (49) | NS | 34 (32) | NS | 29 (27) | NS | 20 (19) | NS | 40 (38) | NS | 25 (24) | NS | 23 (22) | NS | 19 (18) | NS |
| Rectum | 49 | 26 (53) | 27 (55) | 16 (33) | 12 (24) | 10 (20) | 24 (49) | 15 (31) | 10 (20) | 6 (12) | |||||||||
| Depth | |||||||||||||||||||
| pT1 | 12 | 4 (33) | 0.03 | 4 (33) | 0.004 | 0 | 0.003 | 1 (8) | NS | 0 | 0.015 | 1 (8) | 0.003 | 0 | 0.015 | 0 | 0.004 | 0 | 0.009 |
| pT2 | 29 | 8 (28) | 7 (24) | 4 (14) | 5 (17) | 5 (17) | 6 (21) | 4 (14) | 1 (3) | 0 | |||||||||
| pT3 | 105 | 52 (50) | 62 (59) | 42 (40) | 30 (29) | 20 (19) | 52 (50) | 35 (33) | 31 (30) | 24 (23) | |||||||||
| pT4 | 9 | 7 (78) | 6 (67) | 4 (44) | 5 (56) | 5 (56) | 5 (56) | 1 (11) | 1 (11) | 1 (11) | |||||||||
| Lymphatic invasion | |||||||||||||||||||
| Negative | 31 | 9 (29) | 0.044 | 11 (35) | NS | 8 (26) | NS | 7 (23) | NS | 4 (13) | NS | 12 (39) | NS | 8 (26) | NS | 3 (10) | NS | 3 (10) | NS |
| Positive | 124 | 62 (50) | 68 (55) | 42 (39) | 34 (27) | 26 (21) | 52 (42) | 32 (26) | 30 (24) | 22 (18) | |||||||||
| Vascular invasion | |||||||||||||||||||
| Negative | 61 | 24 (39) | NS | 25 (41) | 0.05 | 12 (20) | 0.008 | 15 (25) | NS | 10 (16) | NS | 19 (31) | 0.046 | 8 (13) | 0.005 | 10 (16) | NS | 7 (11) | NS |
| Positive | 94 | 47 (50) | 54 (57) | 38 (40) | 26 (28) | 20 (21) | 45 (48) | 32 (34) | 23 (24) | 18 (19) | |||||||||
| Lymph node status | |||||||||||||||||||
| pN0 | 85 | 37 (44) | NS | 35 (41) | 0.01 | 18 (21) | 0.002 | 18 (21) | NS | 11 (13) | 0.04 | 34 (40) | NS | 18 (21) | NS | 18 (21) | NS | 15 (18) | NS |
| pNx | 70 | 34 (49) | 44 (63) | 32 (46) | 23 (33) | 19 (27) | 30 (43) | 22 (31) | 15 (21) | 10 (14) | |||||||||
| TNM stage | |||||||||||||||||||
| I | 35 | 11 (31) | 0.023 | 9 (26) | <0.001 | 3 (9) | <0.001 | 5 (14) | 0.033 | 4 (11) | 0.031 | 7 (20) | 0.026 | 3 (8) | 0.041 | 1 (3) | <0.001 | 0 | 0.005 |
| II | 43 | 21 (49) | 20 (47) | 11 (26) | 9 (21) | 4 (9) | 21 (49) | 11 (26) | 13 (30) | 11 (26) | |||||||||
| III | 53 | 22 (42) | 31 (58) | 20 (38) | 16 (31) | 14 (26) | 23 (43) | 17 (32) | 8 (15) | 7 (13) | |||||||||
| IV | 24 | 17 (71) | 19 (79) | 16 (67) | 11 (46) | 8 (33) | 13 (54) | 9 (38) | 11 (46) | 7 (29) | |||||||||
| Liver metastatis | |||||||||||||||||||
| Negative | 133 | 55 (41) | 0.001 | 62 (47) | 0.01 | 35 (26) | <0.001 | 30 (23) | 0.016 | 22 (17) | 0.041 | 52 (39) | NS | 32 (24) | NS | 22 (17) | 0.001 | 18 (14) | NS |
| Positive | 22 | 16 (73) | 17 (77) | 15 (68) | 11 (50) | 8 (36) | 12 (55) | 8 (36) | 11 (50) | 7 (32) | |||||||||
| Recurrence | |||||||||||||||||||
| Negative | 119 | 51 (43) | NS | 55 (46) | 0.037 | 29 (24) | <0.001 | 28 (24) | NS | 19 (16) | NS | 40 (34) | 0.001 | 21 (18) | <0.001 | 18 (15) | 0.002 | 12 (10) | 0.001 |
| Positive | 36 | 20 (56) | 24 (67) | 21 (58) | 13 (36) | 11 (31) | 24 (67) | 19 (53) | 15 (42) | 13 (36) | |||||||||
